Concepts (228)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 23 | 2017 | 322 | 2.490 |
Why?
|
| Brain Neoplasms | 18 | 2019 | 587 | 1.500 |
Why?
|
| Gamma Rays | 3 | 2015 | 24 | 0.670 |
Why?
|
| Radiometry | 4 | 2015 | 39 | 0.620 |
Why?
|
| Radiation Oncology | 2 | 2013 | 10 | 0.590 |
Why?
|
| Meningioma | 4 | 2014 | 51 | 0.550 |
Why?
|
| Societies, Scientific | 1 | 2013 | 12 | 0.480 |
Why?
|
| Molecular Imaging | 1 | 2013 | 22 | 0.460 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2014 | 1218 | 0.460 |
Why?
|
| Meningeal Neoplasms | 3 | 2014 | 46 | 0.450 |
Why?
|
| Cranial Irradiation | 5 | 2017 | 84 | 0.430 |
Why?
|
| Brain | 5 | 2015 | 930 | 0.420 |
Why?
|
| Burns | 1 | 2012 | 97 | 0.400 |
Why?
|
| Models, Animal | 1 | 2011 | 160 | 0.390 |
Why?
|
| Skin | 1 | 2012 | 203 | 0.380 |
Why?
|
| Salvage Therapy | 6 | 2015 | 118 | 0.370 |
Why?
|
| Whole-Body Irradiation | 5 | 2015 | 48 | 0.350 |
Why?
|
| Radiation Injuries | 4 | 2017 | 67 | 0.290 |
Why?
|
| Nomograms | 3 | 2015 | 30 | 0.270 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2015 | 337 | 0.270 |
Why?
|
| Carmustine | 1 | 2015 | 8 | 0.260 |
Why?
|
| Male | 28 | 2017 | 17807 | 0.260 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2015 | 40 | 0.250 |
Why?
|
| Trigeminal Neuralgia | 2 | 2015 | 33 | 0.250 |
Why?
|
| Middle Aged | 21 | 2017 | 10829 | 0.250 |
Why?
|
| Humans | 30 | 2019 | 29093 | 0.250 |
Why?
|
| Retrospective Studies | 13 | 2015 | 3111 | 0.250 |
Why?
|
| Treatment Outcome | 13 | 2017 | 3099 | 0.240 |
Why?
|
| Female | 27 | 2019 | 18164 | 0.240 |
Why?
|
| Aged | 18 | 2017 | 9487 | 0.230 |
Why?
|
| Adult | 17 | 2017 | 8420 | 0.220 |
Why?
|
| Animals | 16 | 2019 | 7297 | 0.220 |
Why?
|
| Radiation Injuries, Experimental | 2 | 2015 | 33 | 0.220 |
Why?
|
| Breast Neoplasms | 4 | 2019 | 666 | 0.220 |
Why?
|
| Radiotherapy Dosage | 7 | 2017 | 98 | 0.210 |
Why?
|
| Lung Neoplasms | 3 | 2015 | 384 | 0.190 |
Why?
|
| Treatment Failure | 6 | 2015 | 159 | 0.190 |
Why?
|
| Cognition Disorders | 2 | 2015 | 390 | 0.180 |
Why?
|
| Magnetic Field Therapy | 1 | 2019 | 17 | 0.170 |
Why?
|
| Macaca mulatta | 3 | 2017 | 322 | 0.170 |
Why?
|
| Calcium Channels, T-Type | 1 | 2019 | 29 | 0.170 |
Why?
|
| Disease Models, Animal | 3 | 2019 | 980 | 0.170 |
Why?
|
| Aged, 80 and over | 9 | 2014 | 3717 | 0.160 |
Why?
|
| Follow-Up Studies | 8 | 2015 | 2108 | 0.150 |
Why?
|
| Calcium | 1 | 2019 | 296 | 0.150 |
Why?
|
| Aging | 2 | 2014 | 881 | 0.150 |
Why?
|
| Radiation Dosage | 3 | 2012 | 72 | 0.150 |
Why?
|
| Cerebrovascular Disorders | 1 | 2017 | 48 | 0.150 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2017 | 32 | 0.150 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2016 | 18 | 0.140 |
Why?
|
| Epilepsy | 1 | 2017 | 59 | 0.140 |
Why?
|
| Phantoms, Imaging | 2 | 2015 | 56 | 0.140 |
Why?
|
| Brain Injuries | 1 | 2017 | 94 | 0.140 |
Why?
|
| Calibration | 2 | 2015 | 25 | 0.140 |
Why?
|
| Facial Pain | 2 | 2014 | 21 | 0.140 |
Why?
|
| Central Nervous System Diseases | 1 | 2015 | 11 | 0.130 |
Why?
|
| Pain Measurement | 2 | 2014 | 364 | 0.130 |
Why?
|
| Melanoma | 2 | 2015 | 148 | 0.130 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2012 | 28 | 0.130 |
Why?
|
| Brain Edema | 1 | 2014 | 16 | 0.130 |
Why?
|
| X-Rays | 2 | 2011 | 6 | 0.130 |
Why?
|
| Growth Hormone | 2 | 2013 | 13 | 0.120 |
Why?
|
| Brain Stem Neoplasms | 1 | 2014 | 4 | 0.120 |
Why?
|
| Dog Diseases | 1 | 2013 | 7 | 0.120 |
Why?
|
| Survival Rate | 5 | 2017 | 795 | 0.120 |
Why?
|
| Vein of Galen Malformations | 1 | 2013 | 4 | 0.120 |
Why?
|
| Carcinoma, Small Cell | 1 | 2013 | 21 | 0.120 |
Why?
|
| Cerebral Veins | 1 | 2013 | 11 | 0.120 |
Why?
|
| Health Physics | 1 | 2013 | 4 | 0.120 |
Why?
|
| Radiobiology | 1 | 2013 | 4 | 0.120 |
Why?
|
| Brain Death | 1 | 2013 | 27 | 0.110 |
Why?
|
| Sensitivity and Specificity | 2 | 2011 | 532 | 0.110 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2012 | 27 | 0.110 |
Why?
|
| Radio Waves | 1 | 2012 | 6 | 0.110 |
Why?
|
| Kidney Neoplasms | 2 | 2012 | 192 | 0.110 |
Why?
|
| Temperature | 1 | 2012 | 55 | 0.110 |
Why?
|
| Neurilemmoma | 1 | 2012 | 14 | 0.110 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2013 | 142 | 0.110 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2012 | 14 | 0.110 |
Why?
|
| Cell Proliferation | 2 | 2019 | 573 | 0.110 |
Why?
|
| Cesium Radioisotopes | 1 | 2011 | 5 | 0.100 |
Why?
|
| Reproducibility of Results | 2 | 2011 | 726 | 0.100 |
Why?
|
| Proportional Hazards Models | 4 | 2015 | 709 | 0.100 |
Why?
|
| Disease-Free Survival | 3 | 2013 | 281 | 0.100 |
Why?
|
| Collagen Diseases | 1 | 2011 | 5 | 0.100 |
Why?
|
| Macaca fascicularis | 2 | 2015 | 389 | 0.100 |
Why?
|
| Survival Analysis | 4 | 2013 | 440 | 0.100 |
Why?
|
| Nanotubes, Carbon | 1 | 2011 | 22 | 0.100 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2011 | 30 | 0.100 |
Why?
|
| Vascular Diseases | 1 | 2011 | 61 | 0.100 |
Why?
|
| Adenocarcinoma | 1 | 2013 | 301 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 374 | 0.100 |
Why?
|
| Multiple Sclerosis | 1 | 2011 | 43 | 0.100 |
Why?
|
| Time Factors | 5 | 2014 | 2001 | 0.100 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2012 | 109 | 0.090 |
Why?
|
| Iron | 1 | 2011 | 113 | 0.090 |
Why?
|
| Cognition | 1 | 2014 | 526 | 0.090 |
Why?
|
| Etidronic Acid | 1 | 2009 | 3 | 0.090 |
Why?
|
| Bone Density Conservation Agents | 1 | 2009 | 20 | 0.090 |
Why?
|
| Hippocampus | 1 | 2011 | 185 | 0.090 |
Why?
|
| Mice | 5 | 2019 | 2368 | 0.090 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2015 | 76 | 0.090 |
Why?
|
| Tumor Burden | 3 | 2014 | 60 | 0.090 |
Why?
|
| Glioblastoma | 1 | 2011 | 143 | 0.090 |
Why?
|
| Radiotherapy | 1 | 2009 | 74 | 0.090 |
Why?
|
| Bone and Bones | 1 | 2009 | 87 | 0.090 |
Why?
|
| Osteoporosis | 1 | 2009 | 51 | 0.090 |
Why?
|
| Osteoclasts | 1 | 2008 | 22 | 0.080 |
Why?
|
| Hyperthermia, Induced | 1 | 2011 | 235 | 0.080 |
Why?
|
| Gene Expression Regulation | 1 | 2011 | 481 | 0.080 |
Why?
|
| Osteogenesis | 1 | 2008 | 75 | 0.080 |
Why?
|
| Subtraction Technique | 1 | 2008 | 12 | 0.080 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 2007 | 14 | 0.080 |
Why?
|
| Artificial Intelligence | 1 | 2008 | 49 | 0.080 |
Why?
|
| Rats | 4 | 2014 | 1604 | 0.080 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2008 | 60 | 0.080 |
Why?
|
| Pattern Recognition, Automated | 1 | 2008 | 34 | 0.080 |
Why?
|
| Ovary | 1 | 2007 | 54 | 0.080 |
Why?
|
| Cell Line, Tumor | 3 | 2019 | 680 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 546 | 0.070 |
Why?
|
| Child | 3 | 2014 | 2219 | 0.070 |
Why?
|
| Rats, Inbred F344 | 3 | 2013 | 125 | 0.070 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2008 | 113 | 0.070 |
Why?
|
| Young Adult | 4 | 2014 | 2402 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2009 | 871 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2008 | 162 | 0.070 |
Why?
|
| Risk Assessment | 1 | 2011 | 1305 | 0.070 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 320 | 0.070 |
Why?
|
| Prostatic Neoplasms | 1 | 2009 | 441 | 0.060 |
Why?
|
| Algorithms | 1 | 2008 | 462 | 0.060 |
Why?
|
| Recurrence | 2 | 2015 | 235 | 0.060 |
Why?
|
| Cause of Death | 2 | 2015 | 220 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 525 | 0.060 |
Why?
|
| Stereotaxic Techniques | 2 | 2014 | 23 | 0.060 |
Why?
|
| Radiography | 2 | 2015 | 353 | 0.060 |
Why?
|
| Adolescent | 3 | 2016 | 3254 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 3 | 2010 | 711 | 0.060 |
Why?
|
| Intracranial Hemorrhages | 2 | 2013 | 31 | 0.050 |
Why?
|
| Incidence | 2 | 2015 | 1119 | 0.050 |
Why?
|
| HMGA2 Protein | 1 | 2019 | 13 | 0.040 |
Why?
|
| Electromagnetic Fields | 1 | 2019 | 26 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 57 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 1 | 2019 | 90 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 519 | 0.040 |
Why?
|
| Models, Biological | 1 | 2019 | 373 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2013 | 2019 | 0.040 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2016 | 26 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2017 | 118 | 0.040 |
Why?
|
| Neuronal Plasticity | 1 | 2017 | 81 | 0.040 |
Why?
|
| Air | 1 | 2015 | 6 | 0.030 |
Why?
|
| Hypesthesia | 1 | 2015 | 10 | 0.030 |
Why?
|
| United States | 2 | 2015 | 3630 | 0.030 |
Why?
|
| Water | 1 | 2015 | 50 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2015 | 95 | 0.030 |
Why?
|
| Lymphoid Tissue | 1 | 2015 | 10 | 0.030 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2015 | 22 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2015 | 47 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2015 | 100 | 0.030 |
Why?
|
| Reoperation | 1 | 2015 | 203 | 0.030 |
Why?
|
| Ovariectomy | 1 | 2015 | 147 | 0.030 |
Why?
|
| Spatial Behavior | 1 | 2014 | 9 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2015 | 114 | 0.030 |
Why?
|
| Exploratory Behavior | 1 | 2014 | 30 | 0.030 |
Why?
|
| Brain Stem | 1 | 2014 | 18 | 0.030 |
Why?
|
| Perfusion Imaging | 1 | 2013 | 7 | 0.030 |
Why?
|
| Pituitary Gland | 1 | 2013 | 9 | 0.030 |
Why?
|
| Dogs | 1 | 2013 | 117 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2013 | 80 | 0.030 |
Why?
|
| History, 18th Century | 1 | 2013 | 3 | 0.030 |
Why?
|
| Macrophages | 1 | 2015 | 188 | 0.030 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2013 | 36 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2015 | 514 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2013 | 48 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 159 | 0.030 |
Why?
|
| Pain | 1 | 2015 | 282 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 93 | 0.030 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2013 | 80 | 0.030 |
Why?
|
| Organ Size | 1 | 2013 | 196 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 637 | 0.030 |
Why?
|
| Embolization, Therapeutic | 1 | 2013 | 79 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2012 | 45 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 172 | 0.030 |
Why?
|
| Receptor, erbB-2 | 1 | 2012 | 45 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2012 | 89 | 0.030 |
Why?
|
| Karnofsky Performance Status | 1 | 2012 | 10 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2012 | 37 | 0.030 |
Why?
|
| Pain, Postoperative | 1 | 2014 | 174 | 0.030 |
Why?
|
| Facial Paralysis | 1 | 2011 | 7 | 0.030 |
Why?
|
| Hydrocephalus | 1 | 2011 | 13 | 0.030 |
Why?
|
| Ectodysplasins | 1 | 2011 | 2 | 0.030 |
Why?
|
| Bromodeoxyuridine | 1 | 2011 | 6 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2011 | 10 | 0.030 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2011 | 18 | 0.030 |
Why?
|
| Neurogenesis | 1 | 2011 | 14 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2015 | 1687 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 2011 | 45 | 0.020 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2011 | 33 | 0.020 |
Why?
|
| Functional Laterality | 1 | 2011 | 59 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2012 | 436 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2012 | 92 | 0.020 |
Why?
|
| Microfilament Proteins | 1 | 2011 | 33 | 0.020 |
Why?
|
| Otitis Media | 1 | 2011 | 21 | 0.020 |
Why?
|
| Microglia | 1 | 2011 | 48 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2010 | 68 | 0.020 |
Why?
|
| Contrast Media | 1 | 2011 | 123 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2010 | 22 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2011 | 276 | 0.020 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2011 | 145 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2010 | 160 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 454 | 0.020 |
Why?
|
| Primates | 1 | 2010 | 100 | 0.020 |
Why?
|
| Glioma | 1 | 2011 | 133 | 0.020 |
Why?
|
| Systems Integration | 1 | 2009 | 8 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 248 | 0.020 |
Why?
|
| Prevalence | 1 | 2012 | 896 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 787 | 0.020 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2009 | 18 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2013 | 1167 | 0.020 |
Why?
|
| Artifacts | 1 | 2009 | 38 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 469 | 0.020 |
Why?
|
| Safety | 1 | 2009 | 72 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2011 | 436 | 0.020 |
Why?
|
| Apoptosis | 1 | 2010 | 337 | 0.020 |
Why?
|
| Image Enhancement | 1 | 2008 | 70 | 0.020 |
Why?
|
| Radiographic Image Enhancement | 1 | 2007 | 30 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2012 | 670 | 0.020 |
Why?
|
| Risk Factors | 1 | 2014 | 3531 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2008 | 799 | 0.020 |
Why?
|